Published in final edited form as:

Hum Pathol. 2019 April ; 86: 93–101. doi:10.1016/j.humpath.2019.01.002.

Incidental Non-neoplastic Parenchymal Findings in Patients Undergoing Lung Resection

Yin P Hung, M.D., Ph.D.^{a,1}, Gary M Hunninghake, M.D., M.P.H.^b, Ezra R Miller, M.D.^b, Rachel Putman, M.D.^b, Mizuki Nishino, M.D., M.P.H.^c, Tetsuro Araki, M.D., Ph.D.^c, Hiroto Hatabu, M.D., Ph.D.^c, Lynette M Sholl, M.D.^a, and Marina Vivero, M.D.^a

^aDepartment of Pathology, 75 Francis Street, Brigham and Women's Hospital, Boston, MA, 02115

^bPulmonary and Critical Care Medicine, Department of Medicine, 75 Francis Street, Brigham and Women's Hospital, Boston, MA, 02115

^cDepartment of Radiology, 75 Francis Street, Brigham and Women's Hospital, Boston, MA, 02115

Abstract

The prevalence of incidental non-neoplastic lung disease in patients undergoing resection for mass lesions is unknown. We determined the prevalence and characteristics of parenchymal findings in patients with lung nodules, aiming to increase awareness of findings that could potentially impact patient management. 397 patients with benign or malignant mass lesions with available pre-surgical chest computed tomography scans resected between January 2001 and July 2015 were included. Retrospective histologic assessment of parenchymal abnormalities in at least one section of grossly normal lung was performed for each case by two pulmonary pathologists and correlated with original pathology reports, clinical history, and radiologic findings. 233 women and 164 men underwent resections for carcinomas (78%) or benign nodules (22%). 101 (25%) patients showed parenchymal abnormalities, including 14 patients with multiple findings. The most common abnormal findings were fibrotic interstitial changes (10%), including usual interstitial pneumonia (1%), followed by granulomatous processes (8%). Other findings included aspiration (4%), intravascular thrombi (2%), Langerhans cell histiocytosis (1.5%), small airway obliteration (1%),

Corresponding author: Marina Vivero, M.D., Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; mvivero@partners.org; phone: (617) 732-7510; fax: (617) 277-9015.

¹Permanent address: Department of Pathology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114

AUTHOR CONTRIBUTIONS

Yin P Hung, M.D., Ph.D.: Investigation, data curation, formal analysis, methodology, writing - original draft; writing - review & editing.

Gary M Hunninghake, M.D., M.P.H.: Investigation, funding acquisition, writing - review and editing.

Ezra R Miller, M.D.: Investigation, data curation, writing - review & editing.

Rachel Putman, M.D.: Investigation, writing - review & editing.

Mizuki Nishino, M.D., M.P.H.: Investigation, writing - review & editing.

Tetsuro Araki, M.D., Ph.D.: Investigation, writing - review & editing.

Hiroto Hatabu, M.D., Ph.D.: Investigation, writing - review & editing.

Lynette M Sholl, M.D.: Conceptualization, investigation, methodology, writing - original draft, writing - review & editing.

Marina Vivero, M.D.: Conceptualization, investigation, data curation, formal analysis, methodology, supervision, writing - original draft, writing - review & editing.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

atypical lymphoid infiltrates (1%), and amyloidosis (0.5%). Abnormalities were more likely to have been documented in the original pathology report by pulmonary pathologists (68%) than by general pathologists (15%) ($P < 0.0001$). Cases with histologic parenchymal abnormalities were more likely to show radiologic interstitial lung abnormalities than those without (16% vs. 5%; $P = 0.001$). Evaluation of background lung parenchyma may yield valuable and unanticipated information in patients undergoing surgical resections for lung masses that may correlate with radiographic interstitial lung abnormalities and influence clinical management.

Keywords

Interstitial lung disease; pulmonary fibrosis; usual interstitial pneumonia; aspiration; pulmonary embolism

INTRODUCTION

Over 30,000 surgical lung resections are performed annually in the United States [1], approximately 80–90% for malignant and 10–20% for benign lung nodules [1,2,3]. Reported nonneoplastic findings that account for clinically apparent lesions in lung resections include interstitial fibrosis [3,4], granulomatous inflammation [2,3], and vasculitides [2]. Timely diagnosis of these conditions is crucial for appropriate post-surgical and subsequent patient management. Among the idiopathic interstitial pneumonias, idiopathic pulmonary fibrosis (IPF) is the most common, occurring more frequently in smokers, can be correlated with the development of lung cancer, and has a median survival of 3–5 years that ultimately necessitates lung transplant as the disease progresses [5,6,7,8]. Additionally, IPF, which is characterized by a histologic pattern of usual interstitial pneumonia (UIP), is associated with acute exacerbations and postoperative acute respiratory distress syndrome, resulting in increased morbidity and mortality both among patients with an established diagnosis and those without [9,10,11,12]. In addition to UIP, other non-neoplastic lung diseases, including other interstitial lung diseases, thrombotic angiopathy, constrictive bronchiolitis, and the sequelae of aspiration may be detected in lung resections, with the potential to affect subsequent patient management and prognosis.

While the histologic correlates of benign processes presenting as mass lesions have been described, incidental lung parenchymal abnormalities in resections performed for unrelated mass lesions have not been systematically characterized. In this study, we evaluated a large series of pulmonary resections in patients undergoing surgery for malignant and benign mass-forming lesions at a single institution. We determined the prevalence and characteristics of histologic changes in the background lung parenchyma and correlated our findings to radiologic imaging and clinical outcomes to evaluate their potential clinical significance.

MATERIALS AND METHODS

Patient selection

Following approval of the Institutional Review Board at Brigham and Women's Hospital, we performed a retrospective study of 397 patients: a consecutive series of 307 patients with primary lung adenocarcinoma or poorly differentiated non-small cell carcinoma resected between January 2001 and December 2012, and a consecutive series of 90 patients with benign mass-forming lesions (including hamartomas, intraparenchymal lymph nodes, or inflammatory nodules) resected between January 2001 and July 2015. To correlate pathologic findings with pre-surgical radiologic findings, we included only cases with chest computed tomography (CT) imaging performed at our institution within two months prior to surgery. We excluded patients with squamous cell carcinoma and patients who had undergone neoadjuvant chemotherapy or radiation for lung tumors to minimize confounding effects of post-obstructive pneumonia related to central location and of therapy, respectively, on radiologic and histologic assessment of parenchymal findings. Demographics, clinical history, and radiology reports were obtained from the electronic medical record.

Histologic assessment

Lung tissue sections were selected by the prosector in surgical pathology, with at least one section of lung parenchyma uninvolved by mass lesion routinely obtained in all cases during the study period, per institutional protocol. A median of 2 (range 1–15) whole-tissue hematoxylin and eosin-stained slides containing only non-lesional tissue were reviewed per case by two pulmonary pathologists (MV and LMS). Parenchymal abnormalities were evaluated and categorized according to the following morphologic patterns: fibrotic interstitial changes (including smoking-related interstitial fibrosis [SRIF], usual interstitial pneumonia [UIP], nonspecific interstitial pneumonia [NSIP], and undefined fibrosis), granulomatous disease (including patchy non-specific granulomatous inflammation and sarcoidosis), evidence of possible aspiration, and other findings (intravascular thrombi, Langerhans cell histiocytosis [LCH], constrictive bronchiolitis, amyloidosis, and atypical lymphoid infiltrates). Cases were recorded as suggestive of aspiration, based on modification of recently published criteria [13], if two or more of the four following findings were seen affecting two or more terminal airways: loosely- formed non-necrotizing granulomas and/or giant cells, fibrin, organizing pneumonia, or aspirated material, in the absence of interstitial granulomas away from airways and clinical evidence of infection or hypersensitivity pneumonitis. Small airways disease without clearly recognized clinical correlates or standard clinical management, including respiratory bronchiolitis in the absence of clinical interstitial lung disease and peribronchiolar metaplasia, were not included. Similarly, all instances of organizing pneumonia in the study group were associated with the mass lesions, and were therefore not recorded as separate abnormalities. Where appropriate, additional immunohistochemical or histochemical stains were performed to confirm the diagnosis.

In addition to histologic review, original pathology reports for all cases were also reviewed to determine whether parenchymal findings were documented by the pathologist(s) of record, and whether cases had been reviewed by a general or pulmonary pathologist.

Findings noted in the original reports were correlated with the results of our retrospective review.

Clinical and Radiologic Correlation

Clinical correlates recorded for specific histologic findings are summarized in Table 1. Comprehensive pulmonary function testing was not available in many subjects, and was therefore not recorded as a clinical correlate. Chest CT scans in all cases were evaluated for potential radiologic correlates of histologic findings by up to three readers (radiologists) blinded to prior radiologic interpretations, histology, and clinical history, as previously described [14,15]. Briefly, non-dependent ground-glass abnormalities, reticular abnormalities, diffuse centrilobular nodularity, cysts, honeycombing, and traction bronchiectasis affecting more than 5% of any lung zone were scored as “interstitial lung abnormalities” (ILA). Focal or patchy findings were considered indeterminate.

Statistical Analysis

Statistical significance for group comparison of variables was performed using GraphPad Prism software (GraphPad <http://www.graphpad.com>; version 3.10 for Windows; LaJolla, CA, USA), with a predetermined two-sided *P* value of < 0.05 considered to be statistically significant. The Fisher’s exact test was used when comparing two discrete variables between groups, and the Chi Square test when comparing three or more discrete variables between groups. Continuous variables (age, number of slides) were compared between groups using the two-tailed Mann-Whitney test.

RESULTS

Clinical characteristics

Our study included 406 separate resection specimens from 233 (58.7%) women and 164 (41.3%) men, with a median age of 66.3 (Interquartile range: 59–74). Clinical and pathologic characteristics of study patients are summarized in Table 2. The majority (325, 82%) were either current or former smokers, and most resections (316, 78%) were performed to remove primary lung malignancies. Nine patients had two separate resections, which were evaluated separately for histologic parenchymal abnormalities during the study. Parenchymal abnormalities were identified in 101 of the 397 (25%) patients, including 14 patients with more than one type of abnormality. Median follow-up among patients with abnormalities was 3.6 years (range 2 weeks - 15.8 years), with 86 (85%) patients having at least one year of follow-up. Older age and current or former smoking status were significantly associated with the presence of histologic parenchymal abnormalities ($P = 0.003$ and 0.03 , respectively), while sex, type of resection, and the benign or malignant nature of the nodule were not (Table 2).

Histologic characteristics of non-neoplastic pulmonary parenchymal findings

Histologic characteristics of the non-neoplastic parenchymal findings in the study cohort are summarized in Table 3 and Fig. 1. The relationship between specific categories of parenchymal abnormalities and nodule type or smoking status among all study patients is summarized in Supplemental Table 1. Patients with a smoking history were more likely to

have fibrotic interstitial changes than never smokers (12% vs. 1.4%, $P = 0.007$), and patients with benign disease were more likely than those with malignant disease to harbor parenchymal abnormalities in the “other” category (including thromboembolic disease, lymphoid infiltrates, and constrictive bronchiolitis; 11% vs. 4%, $P = 0.021$).

The specific categories of histologic abnormalities and their clinical correlates are detailed below:

Fibrotic Interstitial Changes—Fibrotic interstitial changes comprised the most common category of histologic findings, noted in 41 (10%) patients. Most cases consisted of SRIF (7%), followed by UIP (1%), NSIP (0.7%), and patterns of “undefined” fibrosis (1%) such as desquamative interstitial pneumonialike patterns, peribronchial fibrosis, and other patterns of fibrosis that did not fall into a recognized category of idiopathic interstitial pneumonia.

Sixteen (53%) patients with SRIF had a clinical diagnosis of COPD, and an additional 9 (30%) had emphysema on chest imaging studies, with no other clinical correlates. One patient with UIP pattern had a known clinical history of nitrofurantoin-induced pulmonary fibrosis, while the other three with a UIP pattern underwent chest CT scans demonstrating unspecified “interstitial fibrosis,” but had no documented clinical diagnosis or treatment related to pulmonary fibrosis during 1.0, 5.4, and 5.5 years of follow-up, respectively. Two of the latter three patients had undergone chemotherapy and radiation for breast cancer and colon cancer 8 and 2 years prior to lung resection, respectively, with agents that have not been associated with pulmonary fibrosis, and otherwise had no histologic or clinical findings suggesting a specific etiology for the interstitial lung disease. No patients with NSIP pattern received rheumatologic or other further workup for interstitial lung disease at the time of last follow-up, at 1.5, 3.0, and 5.5 years. One patient with undefined fibrosis was known to have bleomycin-induced lung injury prior to surgical sampling and was alive at follow-up seven years after surgical sampling. The remainder of the patients within this category did not receive formal diagnoses of or treatment for interstitial lung disease by the time of death or last-follow-up. No patients with fibrotic interstitial changes died of their parenchymal disease.

Granulomatous inflammation—Granulomatous inflammation was identified in 33 (8%) patients, 32 of whom showed a hypersensitivity-type pattern of sparse, poorly-formed granulomas in a peribronchiolar and interstitial distribution. One additional patient was previously diagnosed with sarcoidosis on the basis of mediastinal lymphadenopathy and a prior mediastinal lymph node biopsy containing non-necrotizing granulomas. In 8 of these cases with available material, special stains for microorganisms were performed during diagnostic work-up and were all negative.

In four cases presenting with non-specific granulomatous inflammation, patients complained of chronic cough and/or shortness of breath, including one patient who reported relief with prednisone treatment but did not receive a clinical diagnosis of a specific interstitial lung disease. The single patient with sarcoidosis also had a remote history of metastatic leiomyosarcoma with metastases to the lungs as well as primary lung adenocarcinoma, and remained asymptomatic without treatment during the study period.

Aspiration—Seventeen (4%) patients showed microscopic evidence of aspiration. In nine of these cases (53%), clinical evidence of aspiration was subsequently noted at a mean of 26.6 months after surgery either on swallow studies or during episodes of aspiration pneumonia, two of which resulted in death.

Constrictive Bronchiolitis—Four cases (1%) displayed evidence of constrictive bronchiolitis, characterized by peribronchial fibrosis with luminal narrowing. Three of the four patients were current or former smokers with radiologic evidence of emphysema and/or clinical history of COPD; however, none had documented treatment for their pulmonary disease during the study time period.

Vascular Changes—Organizing or organized thrombi within small arterioles were noted in 8 cases (2%). Four (50%) of these patients experienced subsequent sequelae of thromboembolic disease at a mean of 33 months after surgery. Two were diagnosed with pulmonary hypertension. One of these 2 patients also developed ischemic cerebral infarcts three years after surgery and was discovered to have thoracic aortic and popliteal aneurysms with mural thrombi. One developed bilateral deep vein thromboses two and a half years after surgery and died after a motor vehicle accident related to a transient ischemic attack. One additional patient died of ischemic bowel due to thromboembolic disease three months after surgery.

Two cases (0.5%) showed amyloidosis, with perivascular deposition of eosinophilic, amorphous material confirmed with Congo red stain. One patient had a known history of monoclonal gammopathy of uncertain significance and amyloidosis corroborated on the subsequent lung biopsy performed for an organizing hematoma. The second patient died three months after surgery of complications of small bowel ischemia related to thrombotic disease, as above.

Lymphohistiocytic Proliferations—Langerhans cell histiocytosis (LCH), characterized by nodules or loose aggregates of CD1a and Langerin-positive histiocytoid cells with characteristic nuclear grooves, admixed eosinophils, and scarring [16], was identified in 6 (1.5%) patients. One patient was ultimately diagnosed with LCH based on imaging and smoking history, three patients continued to be followed for small persistent but stable pulmonary nodules without a specific diagnosis, and two patients had no follow-up imaging.

Atypical lymphoid infiltrates with histologic features of nodular lymphoid hyperplasia or non-specific nodular fibroinflammatory lesions, were observed in 4 cases (1%). One patient had a history of hypothyroidism and one developed autoimmune hemolytic anemia; none had documented evolution to a lymphoproliferative disorder at a follow-up of 1.3–14.8 (median 3.7) years.

Impact of specimen type and sampling pattern

The overall prevalence of abnormal parenchymal findings did not significantly differ between specimen types (74 of 267 sub-lobar resections compared to 27 of 139 lobectomy or pneumonectomy specimens; $P = 0.07$, Table 2). While proportions of specimen types did not significantly differ between smokers and non-smokers ($P = 0.68$), more patients with

malignant disease (41%) than with benign disease (10%) underwent lobectomy or pneumonectomy ($P < 0.0001$). Identification of parenchymal abnormalities correlated with the number of sections of background lung sampled, with a median of 3 sections (range 1–15) examined in cases with abnormalities and median of 2 (range 1–11) in those without ($P = 0.0009$).

Reporting Characteristics of Parenchymal Findings

Overall and subspecialty-specific reporting characteristics of parenchymal abnormalities are summarized in Table 3. For the purposes of comparison, original reports of unspecified interstitial fibrosis that was classified as SRIF by the authors during the study were considered concordant, as this terminology was first introduced in 2006 [17,18] and was therefore not uniformly recognized as a specific diagnostic entity during the study period. Twenty-seven (23%) of the 115 abnormalities seen in 101 study specimens were documented in the original pathology reports: Of the 101 study specimens, 85 were originally reviewed by a general pathologist, and 16 specimens were reviewed by a pulmonary pathologist. General pathologists documented 14 of 96 (15%) abnormalities in the original pathology reports, as compared to 13 of 19 (68%) abnormalities documented in abnormal cases reviewed by pulmonary pathologists ($P < 0.0001$). Overall, while general pathologists reported aspiration and most non-fibrotic findings at a rate similar to pulmonary pathologists, pulmonary pathologists were significantly more likely to document findings associated with granulomatous processes ($P = 0.0002$) and fibrotic interstitial changes ($P = 0.005$).

Radiologic correlates associated with non-neoplastic pulmonary parenchymal findings

Radiologic correlates of the non-neoplastic parenchymal findings in this cohort are summarized in Table 4. CT imaging could not be assessed in 12 cases, including 11 cases without and 1 case with histologic parenchymal abnormalities. The presence of histologic abnormalities correlated with the presence of ILA on CT imaging: 16% of cases with histologic abnormalities and 5% of cases without histologic abnormalities showed ILA on CT ($P = 0.001$). Among different histologic categories, only findings consistent with fibrotic interstitial changes were significantly associated with the presence of ILA ($P = 0.002$).

DISCUSSION

Prior to the advent of computed tomography, the majority of surgical lung resections yielded benign nodules [19]. In today's practice, benign diagnoses account for 9–24% of resected nodules [23–20]. Most studies of parenchymal findings in surgical lung resections to date have therefore aimed to define the characteristics of benign pulmonary mass lesions to avoid unnecessary surgery. These studies, however, did not focus on incidental parenchymal findings and excluded specimens with malignant diagnoses, which comprise most resections in the current era of low-dose CT screening [20,21,22].

Our retrospective analysis identified incidental histologic parenchymal abnormalities in 25% of all patients undergoing resection for mass lesions, about a quarter of which were mentioned in the diagnostic pathology report. Pathologists with expertise in pulmonary

diseases were significantly more likely than general pathologists to report these abnormalities.

Chronic fibrotic interstitial changes were the most common parenchymal finding in our study (10% of patients), mostly consisting of SRIF. UP and NSIP patterns of fibrosis, as well as undefined patterns, were seen in 3% of patients, comparable to previously described rates of incidental interstitial pneumonias (1.3–8%) [4,9,23,24]. Interstitial changes, including the specific pattern according to ATS/ERS criteria, were consistently reported by pulmonary pathologists, but only 22% of cases with interstitial changes were reported by general pathologists and were characterized as “subpleural interstitial fibrosis” in all cases. This latter group corresponded to SRIF based on retrospective review. Although the clinical significance and natural history of SRIF are still undetermined, it is highly prevalent, and characterization as SRIF in diagnostic reports is preferable to non-specific descriptions of subpleural fibrosis to prevent misinterpretation as potential UIP, which is characterized by a different histologic pattern of subpleural fibrosis and has a poor prognosis. Consistent with other histopathology studies [2,3,25], interstitial and peribronchial non-necrotizing granulomas were common, identified in 8% of patients in this series. This HP-like pattern has been previously described as a secondary cell-mediated response adjacent to malignant tumors or in regional lymph nodes [26]; however, we also observed granulomas in patients with benign diagnoses, suggesting that the pattern is likely not wholly attributable to antitumor response. Correlation with clinical and radiologic findings, and pulmonary function testing if available, is therefore advisable to evaluate the possibility of hypersensitivity pneumonitis. Other findings, including evidence of aspiration, thrombotic angiopathy, LCH, constrictive bronchiolitis, amyloidosis, and atypical lymphoid infiltrates were each seen in 1–4% of cases.

Importantly, thrombotic angiopathy and aspiration changes were associated with significant subsequent clinical events including ischemic stroke, pulmonary arterial hypertension, small bowel ischemia, and aspiration pneumonia. Together, thrombotic angiopathy and aspiration were seen in 6% of all patients on retrospective review but only one (aspiration changes) was documented in the original pathology report. In contrast, interstitial changes, including those documented as a UIP-pattern, had no clinical phenotype documented in the study period. Interstitial changes did, however, correlate significantly with radiographic interstitial lung abnormalities. There is some evidence to suggest that interstitial changes, particularly in smokers, may interfere with diffusion capacity and contribute to pulmonary symptoms out of proportion to pulmonary function defects based on spirometry [14,15]. Longer term and more systematic follow-up will be required to further characterize these changes.

Non-smokers were more likely to harbor findings in the “other” category (including thrombotic disease, lymphoid infiltrates, or constrictive bronchiolitis) and as likely to have granulomatous inflammation or aspiration. Patients with benign diagnoses were also as likely to have parenchymal abnormalities as those with malignant diagnoses. These findings indicate the importance of evaluating background lung in all patients undergoing resection for mass lesions, regardless of smoking history or diagnosis.

Optimal sampling protocols to evaluate background lung parenchyma in resections performed for nodules are not well established. One previous study evaluated 27 parenchymal sections per case and found SRIF in 39% of cases [27], compared to 7% in this study. The different detection rate may reflect relative undersampling in our cohort, although our approach likely reflects routine diagnostic practice more closely. We did find that parenchymal abnormalities were more likely to be found in cases with 3 or more sampled non-neoplastic areas, an amount that would be feasible in most practices.

The greatest limitations of this study include its retrospective nature, lack of consistent follow-up and pulmonary function testing in the majority of study patients, and its focus on a single tertiary care hospital. Additionally, the inherent difficulty in determining potential mechanical, obstructive, or inflammatory effects of mass lesions on surrounding parenchyma may preclude optimal evaluation of adjacent parenchyma. We attempted to limit overinterpretation of tumor effects by including only changes noted in normal parenchymal sections and attributing findings directly adjacent to tumor as secondary changes.

In summary, our results show that: 1) 77% of incidental parenchymal findings in lung resections performed for mass lesions go unreported, but the majority appear to lack a clear clinical correlate; 2) pulmonary pathologists are significantly more likely than general pathologists to recognize and report the findings; 3) histologic evidence of aspiration and thromboembolic disease, seen in 6% of study patients, may herald subsequent serious clinical events; 4) radiologic ILA are more common in patients with histologic parenchymal abnormalities; and 5) more rigorous sampling of uninvolved lung parenchyma increases the chances of discovering incidental lung parenchymal disease. Our data should be interpreted cautiously in the context of the study's limitations, and additional prospective studies will be necessary to confirm the true clinical impact of our findings in the setting of daily practice. Our results, however, support the judicious use of subspecialty consultation, increased education regarding relevant parenchymal findings, a multidisciplinary diagnostic approach including radiologic evaluation, and thorough sampling of non-neoplastic parenchyma in order to improve diagnostic and clinical outcomes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments:

We thank Dr. Geraldine Pinkus and the immunohistochemistry laboratory, Brigham and Women's Hospital, for technical support.

Funding Sources: This research was supported in part by the National Institutes of Health 5R01HL111024-05.

Declaration of Interest: Yin P Hung, Ezra Miller, Rachel Putman, Tetsuro Araki, Hiroto Hatabu, and Marina Vivero have no disclosures. Mizuki Nishino has performed consulting work for Bristol-Myers Squibb, Toshiba Medical Systems, WorldCare Clinical, and Daiichi Sankyo, has received research grants from Merck, Canon Medical Systems, and AstraZeneca, honoraria from Bayer and Roche, and is supported by R01CA203636 (NCI) and U01CA209414 (none relevant to the current work). Lynette M Sholl performs consulting work for Foghorn Therapeutics and AstraZeneca Pharmaceuticals and is on the scientific advisory board for Loxo Oncology. In the past five years Gary M. Hunninghake has performed consulting work for the Gerson Lehrman Group, Medna LLC, Genentech, and Boehringer-Ingelheim.

This study was presented in part at the 105th Annual Meeting of the United States and Canadian Academy of Pathology (USCAP), Seattle, WA; March 2016 in poster format.

REFERENCES

References

1. Memtsoudis SG, Besculides MC, Zellos L, Patil N, Rogers SO. Trends in lung surgery: United States 1988 to 2002. *Chest*. 2006;130(5):1462–1470. [PubMed: 17099025]
2. Grogan EL, Weinstein JJ, Deppen SA, et al. Thoracic operations for pulmonary nodules are frequently not futile in patients with benign disease. *J Thorac Oncol*. 2011;6(10):1720–1725. [PubMed: 21760552]
3. Smith MA, Battafarano RJ, Meyers BF, Zoole JB, Cooper JD, Patterson GA. Prevalence of benign disease in patients undergoing resection for suspected lung cancer. *Ann Thorac Surg*. 2006;81(5):1824–1828; discussion 1828–1829. [PubMed: 16631679]
4. Saito H, Minamiya Y, Nanjo H, et al. Pathological finding of subclinical interstitial pneumonia as a predictor of postoperative acute respiratory distress syndrome after pulmonary resection. *Eur J Cardiothorac Surg*. 2011;39(2):190–194. [PubMed: 20598898]
5. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med*. 2011;183(6):788–824. [PubMed: 21471066]
6. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. *Br J Cancer*. 2004;91 Suppl 2:S3–10. [PubMed: 15340372]
7. Bouros D, Hatzakis K, Labrakis H, Zeibecoglou K. Association of malignancy with diseases causing interstitial pulmonary changes. *Chest*. 2002;121(4):1278–1289. [PubMed: 11948064]
8. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. *Am J Respir Crit Care Med*. 2000;161(1):5–8. [PubMed: 10619790]
9. Saito Y, Kawai Y, Takahashi N, et al. Survival after surgery for pathologic stage IA nonsmall cell lung cancer associated with idiopathic pulmonary fibrosis. *Ann Thorac Surg*. 2011;92(5):1812–1817. [PubMed: 21944440]
10. Sato T, Teramukai S, Kondo H, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. *J Thorac Cardiovasc Surg*. 2014;147(5):1604–1611 e1603. [PubMed: 24267779]
11. Voltolini L, Bongiolatti S, Luzzi L, et al. Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors. *Eur J Cardiothorac Surg*. 2013;43(1):e17–23. [PubMed: 23129356]
12. Chida M, Ono S, Hoshikawa Y, Kondo T. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. *Eur J Cardiothorac Surg*. 2008;34(4):878–881. [PubMed: 18722134]
13. Cardasis JJ, MacMahon H, Husain AN. The spectrum of lung disease due to chronic occult aspiration. *Ann Am Thorac Soc*. 2014;11(6):865–73. [PubMed: 24950025]
14. Miller ER, Putman RK, Vivero M, et al. Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections. *Am J Respir Crit Care Med*. 2018;197(7):955–958. [PubMed: 28934558]
15. Washko GR, Lynch DA, Matsuoka S, et al. Identification of early interstitial lung disease in smokers from the COPD Gene Study. *Acad Radiol*. 2010;17(1):48–53. [PubMed: 19781963]
16. Sholl LM, Hornick JL, Pinkus JL, Pinkus GS, Padera RF. Immunohistochemical analysis of langerin in langerhans cell histiocytosis and pulmonary inflammatory and infectious diseases. *Am J Surg Pathol*. 2007;31(6):947–952. [PubMed: 17527085]
17. Yousem SA. Respiratory bronchiolitis-associated interstitial lung disease with fibrosis is a lesion distinct from fibrotic nonspecific interstitial pneumonia: a proposal. *Mod Pathol*. 2006;19(11):1474–1479. [PubMed: 16951670]

18. Katzenstein AL, Mukhopadhyay S, Zanardi C, Dexter E. Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens. *Hum Pathol.* 2010;41(3):316–325. [PubMed: 20004953]
19. Steele JD. The Solitary Pulmonary Nodule. Report of a Cooperative Study of Resected Asymptomatic Solitary Pulmonary Nodules in Males. *J Thorac Cardiovasc Surg.* 1963;46:21–39. [PubMed: 14044162]
20. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a metaanalysis. *JAMA.* 2001;285(7):914–924. [PubMed: 11180735]
21. Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstorm RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S. National Lung Screening Trial Research Team. Results of initial low-dose computed tomographic screening for lung cancer. *N Engl J Med.* 2013;368(21):1980–91.
22. Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. *Am J Respir Crit Care Med.* 2015;191(10):1166–75. [PubMed: 25760561]
23. Maniwa T, Kondo H, Mori K, et al. Outcomes in surgically managed non-small-cell lung cancer patients with evidence of interstitial pneumonia identified on preoperative radiology or incidentally on postoperative histology. *Interact Cardiovasc Thorac Surg.* 2015;20(5):641–646. [PubMed: 25712985]
24. Usui K, Tanai C, Tanaka Y, Noda H, Ishihara T. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. *Respirology.* 2011;16(2):326–. [PubMed: 21114711]
25. Madani A, Spicer J, Alcindor T, et al. Clinical significance of incidental pulmonary nodules in esophageal cancer patients. *JGastrointest Surg.* 2014;18(2):226–232; discussion 232–223. [PubMed: 24002773]
26. Steinfert DP, Tsui A, Grieve J, Hibbs ML, Anderson GP, Irving LB. Sarcoidal reactions in regional lymph nodes of patients with early stage non-small cell lung cancer predict improved disease-free survival: a pilot case-control study. *Hum Pathol.* 2012;43(3):333–338. [PubMed: 21835432]
27. Katzenstein AL, Mukhopadhyay S, Zanardi C, Dexter E. Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens. *Hum Pathol.* 2010;41(3):316–325. [PubMed: 20004953]

Highlights

- Incidental parenchymal abnormalities are frequent in lung resections for mass lesions
- Most incidental lung parenchymal findings are under-recognized and under-reported
- The presence of incidental lung abnormalities is unrelated to nature of nodule and smoking status
- Pulmonary thrombotic angiopathy and aspiration may be associated with adverse clinical events

Figure 1. Incidental non-neoplastic pulmonary parenchymal findings (hematoxylin & eosin). (A) patchy granulomatous inflammation (100× magnification), (B) sarcoidosis (100×), (C) smoking-related interstitial fibrosis (40×), (D) usual interstitial pneumonia (40×), (E) usual interstitial pneumonia (200×), (F) non-specific interstitial pneumonia (40×), (G) aspiration (100×), (H) thrombotic angiopathy (100×), (I) Langerhans cell histiocytosis (H&E 200×; inset: Langerin immunohistochemistry, 200×), (J) small airway obliteration (100×), (K) atypical lymphoid infiltrate (100×), (L) amyloidosis (200×).

Table 1.

Clinical Correlates Recorded for Incidental Non-Neoplastic Histologic Findings

Histologic Finding	Clinical Correlates
Interstitial Lung Disease	CT imaging consistent with chronic interstitial lung disease Clinical diagnosis and/or treatment of chronic interstitial lung disease Surgical intervention for diagnosis of pulmonary fibrosis
LCH and non-specific granulomatous inflammation	Radiologic imaging evidence of pulmonary nodules that resulted in further invasive medical intervention (e.g. biopsy, resection)
Aspiration	Treatment for aspiration Positive barium swallow CT imaging consistent with aspiration pneumonia Proton pump inhibitor treatment Clinical history of gastroesophageal reflux symptoms
Thrombotic Angiopathy	Subsequent pathologic evidence of organ infarction Clinical and imaging evidence of pulmonary infarct Clinical and imaging evidence of stroke V/Q scan suggestive of thromboembolic disease Clinical and/or ultrasound evidence of deep venous thrombosis Clinical evidence of pulmonary hypertension
Atypical Lymphoid Proliferation	Prior or subsequent documented clinical or pathologic diagnosis of a lymphoproliferative disorder

Table 2.

Clinical and Pathologic Characteristics of Study Patients in Relation to Presence of Histologic Lung Parenchymal Abnormalities

Characteristic	Total N (%)	Histologically Normal N (%)	Histologically Abnormal N (%)	P value
Age (median, interquartile range)	66.3 (59–74)	65.3 (57–73)	69.3 (62–75)	0.003 *
Sex				
Female	233 (59)	171 (58)	62 (61)	0.56
Male	164 (41)	125 (42)	39 (39)	
Smoking status^a				
Current or Former	325 (82)	236 (80)	89 (90)	0.03 *
Never	69 (18)	59 (20)	10 (10)	
Specimen type^b				
Wedge resection/Segmentectomy	267 (66)	193 (63)	74 (73)	0.07
Lobectomy/Pneumonectomy	139 (34)	112 (37)	27 (27)	
Diagnosis				
<i>Malignant</i>	316 (78)	236 (77)	80 (79)	0.80
Adenocarcinoma ^c	309 (76)	231 (76)	78 (77)	
Poorly differentiated carcinoma	7 (2)	5 (2)	2 (2)	
<i>Benign</i>	90 (22)	69 (23)	21 (21)	
Pulmonary or chondroid hamartoma	61 (15)	50 (16)	11 (11)	
Intraparenchymal lymph node	21 (5)	14 (5)	7 (7)	
Hyaline, fibrous, or fibro-inflammatory nodule	3 (0.7)	1 (0.3)	2 (2)	
Normal lung parenchyma	3 (0.7)	3 (1)	0	
Organizing pneumonia	1 (0.2)	1 (0.3)	0	
Smoking-related pulmonary disease	1 (0.2)	0	1 (1)	

^aSmoking status was unavailable for 3 patients, including 1 without and 2 with histologic lung abnormalities.

^b406 total resections were performed in the 397 study patients, including 296 from patients without and 101 patients with histologic abnormalities.

^cIncludes one case of minimally invasive adenocarcinoma

* Significant value

Table 3.

Histologic and Reporting Characteristics of Non-neoplastic Lung Parenchymal Findings in Study Patients

Lung Parenchymal Abnormality	Instances of Abnormality <i>N</i> = 115 ^a (% total study cases)	Abnormalities Reviewed by General Pathologists		Abnormalities Reviewed by Pulmonary Pathologists		<i>P</i> Value
		Total	# Reported as abnormal (%)	Total	# Reported as abnormal (%)	
Granulomatous processes	33 (8)	27	4 (15)	6	6(100)	0.0002 *
Non-specific granulomatous inflammation	32 (8)	27	4	5	5	
Sarcoidosis	1 (0.2)	0	0	1	1	
Fibrotic Interstitial Changes	41 (10)	37	8 (22)	4	4(100)	0.005 *
Smoking-related interstitial fibrosis ^b	30 (7)	27	8	3	3	
Usual interstitial pneumonia	4 (1)	3	0	1	1	
Non-specific interstitial pneumonia	3 (0.7)	3	0	0	-	
Undefined	4 (1)	4	0	0	-	
Aspiration	17 (4)	12	0 (0)	5	1 (20)	0.29
Other findings	24 (6)	20	2 (10)	4	2 (50)	0.12
Thrombotic angiopathy	8 (2)	7	0	1	0	
Langerhans cell histiocytosis	6 (1.5)	6	1	0	-	
Constrictive bronchiolitis	4 (1)	3	0	1	1	
Atypical lymphoid infiltrate	4 (1)	3	0	1	1	
Amyloidosis	2 (0.5)	1	1	1	0	
Total	115	96	14 (15%)	19	13 (68%)	<0.0001 *

^a14 cases had two separate abnormalities that were considered separate instances of abnormality to be reported.^bSmoking related interstitial fibrosis that was recognized by both general and pulmonary pathologists was reported descriptively.

* Significant values

Table 4.

Radiologic Correlates of Non-neoplastic Lung Parenchymal Findings in Study Patients

	Associated Radiologic Interstitial Lung Abnormalities ^a N (%)			P value
	None	Indeterminate	Present	
Cases without parenchymal abnormalities	190 (65)	87 (30)	16 (5)	0.001 [*]
Total cases with parenchymal abnormalities	54 (47)	44 (39)	16 (14)	
Granulomatous processes	15 (45)	16 (48)	2 (6)	0.11
Non-specific granulomatous inflammation	14 (44)	16 (50)	2 (6)	
Sarcoidosis	1(100)	0 (0)	0 (0)	
Fibrotic Interstitial Changes	21 (51)	11 (27)	9 (22)	0.002 [*]
Smoking-related interstitial fibrosis	20 (67)	7 (23)	3 (10)	
Usual interstitial pneumonia	0 (0)	0 (0)	4(100)	
Non-specific interstitial pneumonia	0 (0)	2 (67)	1 (33)	
Undefined	1 (25)	2 (50)	1 (25)	
Aspiration	7 (44)	6 (38)	3 (19)	0.18
Other findings	11 (46)	11 (46)	2 (8)	0.31
Thrombotic angiopathy	2 (25)	5 (63)	1 (13)	
Langerhans cell histiocytosis	3 (50)	2 (33)	1 (17)	
Small airway obliteration	3 (75)	1 (25)	0 (0)	
Atypical lymphoid infiltrate	3 (75)	1 (25)	0 (0)	
Amyloidosis	0 (0)	2(100)	0 (0)	
Cases with two parenchymal abnormalities	4 (29)	7 (50)	3 (21)	0.038 [*]

^aCT imaging could not be assessed in 12 of 406 cases, including 11 cases without abnormalities and 1 case with abnormality.^{*} Significant values